Related Experiment Video
Updated: May 14, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Farletuzumab in lung cancer
Anish Thomas1, Julia Maltzman, Raffit Hassan
1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.
Abstract:
Folate is essential for proliferating cells and folate transport pathways and folate-dependent metabolic processes show promise as targets for anti-neoplastic therapy. Folate receptor α (FOLR1), a folate transporter, is an attractive target for anti-neoplastic therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. FOLR1 is expressed in non-small cell lung cancer, with a higher expression in adenocarcinoma compared with squamous cell carcinoma. Farletuzumab is a monoclonal antibody targeting FOLR1 which in pre-clinical studies led to cytotoxicity of FOLR1-expressing cells, inhibited tumor growth in animal models and showed limited reactivity with normal tissue. In phase I/II trials, farletuzumab was well tolerated as a single-agent and in combination, without additive toxicity with chemotherapy. An ongoing phase II, double blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1 expressing metastatic adenocarcinoma of lung.
Insights
Folate receptor α (FOLR1) is a promising target for lung cancer therapy. Farletuzumab, an antibody targeting FOLR1, shows potential in treating metastatic lung adenocarcinoma with high FOLR1 expression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Folate is crucial for cell proliferation, making folate pathways potential targets for anti-cancer drugs.
- Folate receptor alpha (FOLR1) is overexpressed in many cancers, including non-small cell lung cancer (NSCLC), particularly adenocarcinoma.
- FOLR1's specific expression in tumors and high affinity for folate make it an attractive therapeutic target.
Purpose of the Study:
- To evaluate the efficacy and safety of farletuzumab, a FOLR1-targeting monoclonal antibody, in patients with metastatic lung adenocarcinoma.
- To investigate farletuzumab's potential as a targeted therapy for FOLR1-expressing lung cancers.
Main Methods:
- Pre-clinical studies demonstrated farletuzumab's ability to induce cytotoxicity in FOLR1-expressing cells and inhibit tumor growth in animal models.
- Phase I/II clinical trials assessed farletuzumab's tolerability as a single agent and in combination with chemotherapy.
- An ongoing Phase II, double-blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1-expressing metastatic lung adenocarcinoma.
Main Results:
- Pre-clinical data showed targeted cytotoxicity and tumor growth inhibition.
- Phase I/II trials indicated farletuzumab was well-tolerated, with no additive toxicity when combined with chemotherapy.
- The ongoing Phase II study aims to confirm efficacy in a larger patient cohort.
Conclusions:
- Farletuzumab is a well-tolerated agent with pre-clinical evidence of anti-tumor activity.
- Targeting FOLR1 represents a viable strategy for treating metastatic lung adenocarcinoma.
- Further evaluation in the ongoing Phase II trial is critical to establish farletuzumab's clinical benefit.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
